<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4"><strong>Toxoplasmosis – Laboratory Diagnosis, Investigation, Treatment and Management (incl. Pregnancy)</strong></h1><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1. Infectious Agent and Lifecycle</strong></h2><ul><li><em>Toxoplasma gondii</em> – obligate intracellular protozoan (Apicomplexa).</li><li>Forms:<ul><li><strong>Oocysts</strong> - shed in cat faeces; infectious after sporulation.</li><li><strong>Tachyzoites</strong> – rapidly replicating; cause acute disease.</li><li><strong>Bradyzoites</strong> in tissue cysts – latent infection (brain, muscle, eye).</li><li><strong>Gametocytes</strong> – sexual reproduction in definitive host (cat).</li></ul></li><li>Transmission:<ul><li>Ingestion of oocysts from contaminated food/water/soil, cat litter.</li><li>Ingestion of tissue cysts from undercooked meat.</li><li><strong>Vertical</strong>: maternal–fetal during primary maternal infection.</li><li>Rare: organ transplantation, transfusion.</li></ul></li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>2. Clinical Manifestations</strong></h2><p><strong>Immunocompetent</strong>: Often asymptomatic; may present with fever, lymphadenopathy, myalgia.</p><p><strong>Immunocompromised (e.g. HIV, transplant, chemotherapy)</strong>: Severe encephalitis, chorioretinitis, myocarditis, pneumonia, disseminated infection (often reactivation).</p><p><strong>Pregnancy</strong>:</p><ul><li>Transmission risk increases with gestation (15% 1st trimester → 70% 3rd).</li><li>Severity decreases with gestation (early infection → severe CNS/ocular damage; later infection → often subclinical at birth, but may cause delayed sequelae).</li><li><strong>Congenital toxoplasmosis</strong>: Hydrocephalus, intracranial calcification, chorioretinitis, developmental delay; may present at birth or later.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3. Specimens for Diagnosis</strong></h2><p><strong>Fluids</strong>: Blood, CSF, BAL, vitreous/aqueous humour, urine, pleural, peritoneal, ascitic fluid.</p><p><strong>Tissue</strong>: Placenta, fetal tissue, lymph node, brain, skeletal/cardiac muscle, eye.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>4. Laboratory Diagnosis</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Serology (Mainstay)</strong></h3><ul><li><strong>IgG</strong>: Appears within 1–2 weeks, peaks ~8 weeks, persists lifelong. Negative = no prior infection (but beware early acute or severe immunodeficiency).</li><li><strong>IgM</strong>: Appears within 1 week of infection, but may persist months–years. Negative essentially rules out recent infection (&lt;6 months). False positives occur.</li><li><strong>IgA/IgE</strong>: Useful markers of acute infection, esp. in pregnancy; disappear sooner than IgM.</li><li><strong>IgG avidity</strong>:</li></ul><p>High avidity → infection &gt;12–16 weeks earlier.</p><p>Low/equivocal avidity can persist months; not definitive.</p><p><strong>Specialist tests</strong>:</p><ul><li>Sabin–Feldman dye test (IgG; reference only).</li></ul><p><strong>Key principle</strong>: Interpretation requires <strong>combination of tests</strong>; reference laboratory consultation essential in pregnancy/immunocompromised.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Direct Detection</strong></h3><ul><li><strong>PCR</strong>:</li></ul><p>Detects <em>T. gondii</em> DNA in fluids/tissues.</p><p>High specificity (~100%), sensitivity variable (blood 15–85%, CSF 11–77%).</p><p>Amniotic fluid PCR (≥18 wks GA, ≥4 wks post maternal infection) confirms congenital infection.</p><p>May detect DNA from latent organisms.</p><ul><li><strong>Microscopy/Histology</strong>:</li></ul><p>Tachyzoites in tissue/fluids diagnostic.</p><p>Tissue cysts, esp. with inflammation, also significant.</p><p>Giemsa/Wright stains; IHC increases yield.</p><ul><li><strong>Culture</strong>:</li></ul><p>Isolation via mouse inoculation or tissue culture; rarely used in routine labs.</p><ul><li><strong>Radiology</strong>:</li></ul><p>CNS: MRI &gt; CT; multiple ring-enhancing lesions with oedema (esp. thalamus, grey–white junction).</p><p>Congenital: intracranial calcification, ventriculomegaly, hydrocephalus.</p><p>Chest CT: ground-glass opacities, nodules.</p><ul><li><strong>Other lab findings</strong>:</li></ul><p>↑ LDH (esp. pulmonary toxoplasmosis in AIDS).</p><p>CSF: high protein (&gt;500 mg/dL) in congenital; PCR useful.</p><p>Peripheral eosinophilia absent (differentiates from helminthic infections).</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>5. Investigations in Pregnancy / Neonates</strong></h2><p><strong>Maternal</strong>:</p><p>Screen: IgG + IgM.</p><p>IgM+/IgG– → repeat to confirm acute infection.</p><p>IgM+/IgG+ → perform avidity testing.</p><p><strong>Fetal</strong>:</p><p>Amniotic fluid PCR (after 18 wks).</p><p>Serial US: ventriculomegaly, hepatosplenomegaly, growth restriction.</p><p><strong>Neonate</strong>:</p><p>Serology: IgM/IgA, persistence of IgG &gt;12 months.</p><p>Cranial US/MRI, ophthalmology, CSF.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6. Treatment Principles</strong></h2><p><strong>Only tachyzoites are killed</strong>; bradyzoites persist.</p><p>Drugs block <strong>folate metabolism</strong>, so folinic acid needed.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Key Drugs</strong></h3><ul><li><strong>Pyrimethamine</strong>: Loading 200 mg PO, then 50–75 mg/day.</li></ul><p>Side effect: marrow suppression → folinic acid required (10–25 mg/day).</p><p><em>Do not substitute folic acid</em>.</p><ul><li><strong>Sulfadiazine</strong>: 1–1.5 g QID PO (max 4 g/day in pregnancy).</li><li><strong>Folinic acid (leucovorin)</strong>: Prevents marrow toxicity.</li><li><strong>Clindamycin</strong>: 600 mg QID PO/IV if sulfa-allergic.</li><li><strong>Atovaquone</strong>: Alternative agent.</li><li><strong>TMP-SMX</strong>: Effective, especially for prophylaxis in HIV.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>7. Treatment by Clinical Context</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Immunocompetent</strong></h3><p>Often self-limiting; no Rx unless:</p><p>Ocular disease, myocarditis, hepatitis, encephalitis.</p><p>Severe/persistent disease.</p><p>Rx: pyrimethamine + sulfadiazine (or clindamycin) × 2–4 wks.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Immunocompromised</strong></h3><p><strong>Acute CNS/pulmonary disease</strong>: pyrimethamine + sulfadiazine + folinic acid.</p><p>Alternatives: pyrimethamine + clindamycin; atovaquone.</p><p>Empiric therapy often started in HIV with low CD4 and suggestive MRI.</p><p>If no response in 10–21 days → brain biopsy.</p><p>Rx duration: ≥6 wks then maintenance until immune recovery.</p><p><strong>Prophylaxis</strong>: TMP-SMX (also covers <em>Pneumocystis</em>).</p><p>HIV: if CD4 &lt;100 and IgG positive.</p><p>Transplant: protocol dependent.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Pregnancy</strong></h3><p><strong>Maternal infection</strong>:</p><p>Spiramycin (1 g PO q8h) until delivery if no confirmed fetal infection.</p><p>Reduces transmission (esp. &lt;14 weeks).</p><p><strong>Confirmed fetal infection (PCR+, abnormal US, &gt;14 wks GA)</strong>:</p><p>Pyrimethamine + sulfadiazine + folinic acid.</p><p>Pyrimethamine avoided &lt;12–14 wks (teratogenic).</p><p>Alternate: monthly alternating spiramycin and triple therapy.</p><p><strong>HIV-positive pregnant women</strong>: specialist consultation, as reactivation risk higher.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Congenital infection (neonate)</strong></h3><p><strong>Pyrimethamine + sulfadiazine + folinic acid</strong> for 12 months.</p><p>Monitor: CBC, ophthalmology, neuroimaging, development.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>8. Prevention</strong></h2><ul><li><strong>Food safety</strong>:</li></ul><p>Avoid raw/undercooked meat (cook &gt;67 °C, freeze –20 °C × 48h).</p><p>Wash fruit/veg.</p><p>Avoid unpasteurised goat milk, raw shellfish.</p><ul><li><strong>Cat/litter precautions</strong>:</li></ul><p>Avoid handling litter/soil; use gloves.</p><p>Clean litter daily; oocysts need 1–5 days to sporulate.</p><ul><li><strong>Counselling</strong>:</li></ul><p>Pregnant &amp; immunocompromised should be warned if seronegative.</p><ul><li><strong>Screening</strong>:</li></ul><p><strong>Not routine in UK</strong> (per UK NSC).</p><p>Some European countries (e.g. France, Austria) have antenatal screening.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>9. Summary Table</strong></h2><table><tr><td><p><strong>Situation</strong></p></td><td><p><strong>Investigation</strong></p></td><td><p><strong>Treatment</strong></p></td></tr><tr><td><p>Maternal suspected acute infection</p></td><td><p>IgM/IgG, </p><p>IgG avidity; </p><p>repeat serology</p></td><td><p>Spiramycin until delivery (if fetus not infected)</p></td></tr><tr><td><p>Confirmed fetal infection (PCR+)</p></td><td><p>Amniotic fluid PCR, serial US</p></td><td><p>Pyrimethamine + sulfadiazine + folinic acid (&gt;14 wks GA)</p></td></tr><tr><td><p>Neonatal congenital toxoplasmosis</p></td><td><p>Serology, </p><p>imaging, ophthal. exam</p></td><td><p>Triple therapy × 12 months</p></td></tr><tr><td><p>Immunocompromised (CNS, disseminated)</p></td><td><p>PCR (blood/CSF), MRI, serology</p></td><td><p>Pyrimethamine + sulfadiazine + folinic acid; alternatives as above</p></td></tr><tr><td><p>Prophylaxis</p></td><td><p>Serostatus, CD4 count (HIV)</p></td><td><p>TMP-SMX</p></td></tr></table>
</div>